Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease

被引：44
作者：
Sullivan, AM
OpackaJuffry, J
Hotten, G
Pohl, J
Blunt, SB
机构：
[1] HAMMERSMITH HOSP,MRC,CYCLOTRON UNIT,LONDON W12 0NN,ENGLAND
[2] BIOPHARM GMBH,D-69115 HEIDELBERG,GERMANY
来源：
NEUROSCIENCE LETTERS | 1997年 / 233卷 / 2-3期
关键词：
growth/differentiation factor 5; neuroprotection; nigrostriatal lesion; 6-hydroxydopamine; dopamine; Parkinson's disease; positron emission tomography;
D O I：
10.1016/S0304-3940(97)00623-X
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Growth/differentiation factor 5 (GDF5), a novel member of the transforming growth factor beta superfamily, promotes the survival of dopaminergic neurones in vitro. We present here the first evidence for a neuroprotective action of GDF5 in vivo. We investigated the effects of intracerebral administration of GDF5 on a rat model of Parkinson's disease. GDF5 was administered just above the substantia nigra and into the lateral ventricle immediately before ipsilateral injection of 6-hydroxydopamine into the medial forebrain bundle. GDF5 prevented the development of amphetamine-induced rotations and preserved the integrity of striatal dopaminergic nerve terminals, as measured by positron emission tomography. Post-mortem studies showed that GDF5 spared dopamine levels in the striatum and tyrosine hydroxylase positive neurones in the midbrain. This study suggests that GDF5 has potential for the treatment of Parkinson's disease. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码：73 / 76
页数：4
相关论文
共 50 条
[41]   Oestrogen and nigrostriatal dopaminergic neurodegeneration: Animal models and clinical reports of Parkinson's disease [J].
Liu, Bin ;
Dluzen, Dean E. .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (07) :555-565
[42]   Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease [J].
Xi-Xun Du ;
Hua-Min Xu ;
Hong Jiang ;
Ning Song ;
Jun Wang ;
Jun-Xia Xie .
Neuroscience Bulletin, 2012, 28 :253-258
[43]   Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease [J].
Reglödi, D ;
Lubics, A ;
Tamás, A ;
Szalontay, L ;
Lengvári, I .
BEHAVIOURAL BRAIN RESEARCH, 2004, 151 (1-2) :303-312
[44]   Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease [J].
Drui, G. ;
Carnicella, S. ;
Carcenac, C. ;
Favier, M. ;
Bertrand, A. ;
Boulet, S. ;
Savasta, M. .
MOLECULAR PSYCHIATRY, 2014, 19 (03) :358-367
[45]   Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease [J].
Gouhier, C ;
Chalon, S ;
Aubert-Pouessel, A ;
Venier-Julienne, MC ;
Jollivet, C ;
Benoit, JP ;
Guilloteau, D .
SYNAPSE, 2002, 44 (03) :124-131
[46]   Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson’s Disease [J].
Mohd. Moshahid Khan ;
Syed Shadab Raza ;
Hayate Javed ;
Ajmal Ahmad ;
Andleeb Khan ;
Farah Islam ;
Mohammed M. Safhi ;
Fakhrul Islam .
Neurotoxicity Research, 2012, 22 :1-15
[47]   Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway [J].
Booij, Jan ;
Berendse, Henk W. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 310 (1-2) :40-43
[48]   Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease [J].
G Drui ;
S Carnicella ;
C Carcenac ;
M Favier ;
A Bertrand ;
S Boulet ;
M Savasta .
Molecular Psychiatry, 2014, 19 :358-367
[49]   Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson's Disease [J].
Khan, Mohd Moshahid ;
Raza, Syed Shadab ;
Javed, Hayate ;
Ahmad, Ajmal ;
Khan, Andleeb ;
Islam, Farah ;
Safhi, Mohammed M. ;
Islam, Fakhrul .
NEUROTOXICITY RESEARCH, 2012, 22 (01) :1-15
[50]   Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model [J].
Sawada, H ;
Ibi, M ;
Kihara, T ;
Honda, K ;
Nakamizo, T ;
Kanki, R ;
Nakanishi, M ;
Sakka, N ;
Akaike, A ;
Shimohama, S .
NEUROPHARMACOLOGY, 2002, 42 (08) :1056-1064
12345